Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia.
Weight loss in advanced cancer patients is refractory to conventional nutritional support. This may be due to metabolic changes mediated by proinflammatory cytokines, hormones, and tumor-derived products. We previously showed that a nutritional supplement enriched with fish oil will reverse weight loss in patients with pancreatic cancer cachexia. The present study examines the effect of this supplement on a number of mediators thought to play a role in cancer cachexia. Twenty weight-losing patients with pancreatic cancer were asked to consume a nutritional supplement providing 600 kcal and 2 g of eicosapentaenoic acid per day. At baseline and after 3 wk, patients were weighed and samples were collected to measure serum concentrations of interleukin (IL)-6 and its soluble receptor tumor necrosis factor receptors I and II, cortisol, insulin, and leptin, peripheral blood mononuclear cell production of IL-1 beta, IL-6, and tumor necrosis factor, and urinary excretion of proteolysis inducing factor. After 3 wk of consumption of the fish oil-enriched nutritional supplement, there was a significant fall in production of IL-6 (from median 16.5 to 13.7 ng/ml, P = 0.015), a rise in serum insulin concentration (from 3.3 to 5.0 mU/l, P = 0.0064), a fall in the cortisol-to-insulin ratio (P = 0.0084), and a fall in the proportion of patients excreting proteolysis inducing factor (from 88% to 40%, P = 0.008). These changes occurred in association with weight gain (median 1 kg, P = 0.024). Various mediators of catabolism in cachexia are modulated by administration of a fish oil-enriched nutritional supplement in pancreatic cancer patients. This may account for the reversal of weight loss in patients consuming this supplement.
Barber
M D
MD
University Department of Surgery, Royal Infirmary of Edinburgh, Edinburgh EH3 9YW, UK.
Fearon
K C
KC
Tisdale
M J
MJ
McMillan
D C
DC
Ross
J A
JA
D000293:Adolescent; D000328:Adult; D000368:Aged; D001798:Blood Proteins / Q000652:urine; D002100:Cachexia / Q000209:etiology / Q000378:metabolism* / Q000628:therapy*; D019587:Dietary Supplements; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage; D002149:Energy Intake; D005260:Female; D005395:Fish Oils / Q000008:administration & dosage*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007328:Insulin / Q000097:blood; D015850:Interleukin-6 / Q000096:biosynthesis / Q000097:blood; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000150:complications* / Q000473:pathology; D011509:Proteoglycans
D001798:Blood Proteins; D005395:Fish Oils; D007328:Insulin; D015850:Interleukin-6; D008070:Lipopolysaccharides; D011509:Proteoglycans; C042057:proteolysis-inducing peptide; D015118:Eicosapentaenoic Acid; D006854:Hydrocortisone